Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
96 participants were randomly assigned to groups of 6 multiple-ascending doses of once-weekly subcutaneous cagrilintide (final doses of 0.16, 0.30, 0.60, 1.2, 2.4, and 4.5 mg) in combination with once-weekly subcutaneous semaglutide 2.4 mg or semaglutide 2.4 mg with placebo for 20 weeks
Ozempic is the brand name for semaglutide GLP-1 when it is prescribed for managing type 2 diabetes
Finally, as a newer provider, long-term outcomes and large review datasets are still sparse
This means you draw your dose using a syringe, which requires understanding unit-to-milligram conversions
GLP-1 therapy may be appropriate for adults with a BMI of 30+, or a BMI of 27+ with a related condition like high blood pressure or type 2 diabetes
Some patients successfully transition to maintenance doses lower than those required for active weight loss
